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ABSTRACT (417 words/ MAX 425)  
 
Objectives: Novel rationales for randomizing clusters rather than individuals appear to be 
emerging from the push for more pragmatic trials, for example to facilitate trial recruitment, 
reduce the costs of the research, and improve external validity. Such rationales may be driven by 
a mistaken perception that choosing cluster randomization lessens the need for informed consent. 
We reviewed a random sample of published cluster randomized trials (CRTs) involving only 
individual-level health care interventions to determine: (a) the prevalence of reporting a rationale 
for the choice of cluster randomization; (b) the types of explicit, or if absent, apparent rationales 
for the use of cluster randomization; (c) the prevalence of reporting patient informed consent for 
study interventions; and (d) the types of justifications provided for waivers of consent. We 
considered CRTs evaluating exclusively individual-level health care interventions to focus on 
clinical trials where individual randomization is theoretically possible and where there is a 
general expectation of informed consent.  
Design: A random sample of 40 CRTs identified through implementing a validated electronic 
search filter in two electronic databases (Ovid Medline and Embase) with two reviewers 
independently extracting information from each trial.  
Setting: Inclusion criteria were: primary report of a CRT; evaluating exclusively an individual-
level health care intervention(s); published between 2007-2016; and conducted in Canada, USA, 
European Union, Australia, or low-and-middle-income country (LMIC) settings.  
Results: Twenty-five trials (62.5%, 95% confidence interval (CI) 47.5 to 77.5%) reported an 
explicit rationale for the use of cluster randomization. The most commonly reported rationales 
were logistical or administrative convenience (15 trials, 60%) and the need to avoid 
contamination (13, 52%); 5 trials (20%) cited rationales related to the push for more pragmatic 
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trials. Twenty-one trials (52.5%, 95% CI 37 to 68%) reported written informed consent for the 
intervention, 2 (5%) reported verbal consent, 8 (20%) reported waivers of consent, while in 9 
(22.5%) consent was unclear or not mentioned. Reported justifications for waivers of consent 
included that study interventions were already used in clinical practice, patients were not 
randomized individually, and to facilitate the pragmatic nature of the trial. Only one trial 
reported an explicit and appropriate justification for waiver of consent based on minimum 
criteria in international research ethics guidelines, namely infeasibility and minimal risk.  
Conclusions: Rationales for adopting cluster over individual randomization and for adopting 
consent waivers are emerging, related to the need to facilitate pragmatic trial aims. Greater 
attention to clear reporting of study design rationales, informed consent procedures, as well as 
justification for waivers is needed to ensure that such trials meet appropriate ethical standards. 
 
KEY WORDS 
Cluster randomized trials; pragmatic trials; informed consent; research ethics review; waivers of 
consent  
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INTRODUCTION 
In an individually randomized controlled clinical trial, patients are independently 
recruited (after soliciting their informed consent), randomized to receive one or more 
experimental or control interventions, and observed for their outcomes. In a cluster randomized 
trial (CRT) however, the units of randomization are groups such as hospitals or medical 
practices, while the units of observation are the patients.1 A key implication of cluster 
randomization is that, because outcomes from multiple patients in the same cluster are usually 
positively correlated, a larger sample size is required than if individual randomization were 
used.1 The sample size inflation factor is a function of the cluster size and the intracluster 
correlation coefficient, and can be substantial. For example, with a commonly assumed 
intracluster correlation coefficient of 0.05 and a cluster size of 100, the number of patients 
required for a parallel arm CRT is six times that under individual randomization. Another key 
implication is that CRTs are subject to increased risks of bias. Often, individual patients must be 
identified and recruited after cluster randomization and unless this is done blinded to the cluster’s 
allocation (which can be difficult or impossible to ensure), differential inclusion of patients may 
result.2,3 CRTs typically randomize fewer units than individually randomized trials, and although 
the risks of chance bias due to baseline imbalances do not necessarily decrease with sample size,4 
interpretation of trial results may be more complicated when substantial baseline differences 
exist. As it is unethical to expose people to research risks without adequate social value, a clear 
justification for the use of cluster randomization is required.5,6 The recently revised Council for 
International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines for 
Health-related Research Involving Humans, for example, holds that adequate social value is a 
necessary condition for ethically acceptable research with humans and that “[i]t is essential to the 
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social value of health-related research that its design is scientifically sound and that it offers a 
means of developing information not otherwise obtainable.”7 Providing an acceptable rationale 
for choosing cluster, as opposed to individual, randomization should therefore establish why the 
increased risks of bias and the use of larger sample sizes are justified relative to the alternative of 
an individually randomized trial. In this manuscript, we consider ethical issues raised by the 
choice of cluster over individual randomization. 
CRTs may involve several different types of intervention. The nature of the intervention 
can influence the rationale for a CRT. Where cluster randomised trials involve interventions 
referred to as “cluster-cluster” and “professional-cluster” interventions,8 the choice of cluster 
randomization is obvious as individual randomization is simply not feasible. A cluster-cluster 
intervention is such that it can only be delivered to the entire cluster, i.e., it is not divisible at the 
individual-level (for example, an engineering system to reduce the saltwater content of central 
water supplies in rural coastal areas).9 A professional-cluster intervention is delivered to health 
providers (for example, education to improve their prescribing practices).10 However, in this 
paper, we examine CRTs that only include “individual-cluster” interventions, in particular, 
clinical interventions such as supplementation of pregnant women with vitamin A or beta 
carotene.11 In these trials, patients could theoretically opt out of receiving interventions and 
individual randomization is therefore possible. While no explicit guidance exists to determine 
what are acceptable rationales for adopting cluster randomization, commonly used rationales and 
their application to individual-level health care interventions, are summarized in Supplementary 
Table 1. The burden is on investigators to justify their choice of study design, although the 
legitimacy of such justifications can often be difficult to determine.  
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In recent years, there has been a renewed interest in the use of cluster randomization for 
pragmatic comparative effectiveness research, designed to compare the benefits and harms of 
alternative methods to prevent, diagnose, treat and monitor a clinical condition or to improve the 
delivery of care in real-world (as opposed to optimized) conditions.12,13 Key considerations in 
discussions about study designs for pragmatic comparative effectiveness research are 
generalizability, logistics and costs of the research, with cluster randomization being perceived 
as offering advantages over individual randomization. For example, individual randomization 
has been described as onerous and costly, while cluster randomization is the preferred method to 
evaluate questions of effectiveness due to “their enhanced external validity and lower costs”.14 
We have identified such statements as a concern,15 indicating that investigators might be 
conflating the use of cluster randomization with waivers of informed consent. Because CRTs 
require more patients (and usually more centers) than individually randomized trials, CRTs may 
cost more than individually randomized trials, holding consent procedures fixed. Likewise, CRTs 
do not necessarily translate to greater external validity; individually randomized trials can be 
designed to be highly pragmatic and generalizable. The perception that cluster randomization by 
itself increases the degree of pragmatism and external validity may rest on the misperception that 
the design facilitates inclusion of whole clusters without the need for informed consent. Others 
have explicitly argued that “consent for the intervention is not relevant in a cluster randomized 
trial because patients receive the same treatment regardless of whether or not they consent.”16 
Moreover, two recently published articles on pragmatic trials referred to CRTs as being able to 
help avoid or lessen the need for informed consent.17,18 However, informed consent is a 
fundamental requirement in international research ethics guidance: a research ethics committee 
may approve a modification or waiver of informed consent only if the research would not be 
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feasible without the waiver or modification, the research has important social value, and the 
research poses no more than minimal risk to participants.7 If researchers and research ethics 
committees are mistakenly accepting design rationales that amount to the ability to circumvent 
established research ethics requirements, then it creates the potential for the inadvertent or 
explicit gaming of the research ethics system.19 
In this study, our primary objectives were to examine rationales for using cluster 
randomization, as well as reporting of informed consent and justifications for waivers of consent 
in a random sample of trials exclusively evaluating individual-cluster interventions. Our focus is 
on CRTs where clusters consist of multiple individuals, as opposed to CRTs where each 
individual constitutes a cluster and provides multiple observations, say, on different body parts. 
Our hypothesis was that there are emerging justifications for adopting cluster randomization 
stemming from the rising interest in pragmatic trials, but that these may be accompanied by the 
mistaken perception that choosing cluster randomization lessens the need for informed consent. 
As it is improbable that investigators would explicitly state that they chose cluster randomization 
to avoid seeking informed consent, we set out to determine: (a) the prevalence of reporting a 
rationale for the choice of cluster randomization; (b) the types of explicit, or if absent, apparent 
rationales for the use of cluster randomization; (c) the prevalence of reporting informed consent 
for study interventions; and (d) the types of justifications provided for waivers of consent.  
 
METHODS 
Identification of relevant articles 
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We adapted our previously published and validated electronic search filter to identify 
CRTs published during or after 2007 to cover a 10-year period at the time of the search.20 We 
considered trials published in the past 10 years because this corresponds to a period with 
increasing attention on pragmatic comparative effectiveness research. The search filter, presented 
in Supplementary Table 2, was implemented on 16 November 2016 in two databases: Ovid 
Medline and Embase. The records were manually de-duplicated and imported into Covidence 
software.21 Title and abstract screening was a two-stage process: two reviewers (MT, ARH) 
independently screened records to identify “possible CRTs”, followed by two reviewers (MT, 
KC) independently screening this subset of records to identify primary reports of CRTs. Records 
were excluded if they were a protocol or design paper, secondary outcome analysis, process 
evaluation, or baseline evaluation.  
All citations of possible primary reports of CRTs were then exported to an Excel 
spreadsheet. To operationalize random selection, we generated a uniform random number for 
each record using Excel's RAND function and then ordered the records by that number. A single 
reviewer (KC) then screened the full text articles for each record in sequence until our target 
sample size was achieved. Inclusion criteria were: a) primary report of a CRT; b) evaluating an 
exclusively individual-level health care intervention; and c) conducted in Canada, USA, 
European Union, Australia, or LMIC settings (the countries in which our investigator team has 
experience). Individual-level interventions were defined as any intervention that is divisible 
(implemented) at the individual-level; thus, CRTs were excluded if they evaluated a complex 
intervention that involved cluster-level or professional-level interventions. Health care 
interventions were defined as any pharmacological interventions, pharmacological treatment 
strategies (e.g., different timing of taking medications), surgical interventions, implantable or 
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non-implantable devices, rehabilitation, diet, or other types of clinical interventions. Trials of 
public health, and health promotion and prevention interventions were excluded. Thus, we 
considered clinical trials in which individual randomization might be possible and where there is 
a general expectation of patient informed consent.  
Sample size 
Our target sample size was 40 trials, based on being able to conduct the review within the 
constraints of an unfunded study.  
Data abstraction 
Data abstraction forms used in our previous reviews22,23 were adapted for the specific 
purposes of this review, and pilot tested using an initial convenience sample of eight eligible 
CRTs identified through PubMed searches. All five reviewers (MT, SGN, KC, ARH, and CEG) 
participated in the pilot testing and any discrepancies in abstraction were resolved by discussion 
among all reviewers. The remaining 32 trials were then distributed amongst the reviewers and 
abstracted independently by two reviewers per trial. Each reviewer pair included both ethics and 
methods expertise. After each batch of three trials had been abstracted, discrepancies were 
reviewed within the pair and resolved by consensus. If differences could not be resolved, either 
CW or MT were final arbitrators. The primary source of information for each trial was the 
published report, but we accessed any supplementary information that was available online, 
including study protocols, supplementary information or informed consent sheets.  
Data were abstracted on trial characteristics, including publication year, country of study 
recruitment, type of cluster, and study design. We also extracted whether the study was self-
identified as a pragmatic trial, and the reported use of a data safety monitoring committee and 
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research ethics review. We recorded detailed information about study interventions and data 
collection procedures in each arm of the trial. If there was more than one trial arm, abstractors 
were asked to reach consensus, before extractions, in classifying one arm as the main 
intervention arm and one arm as the comparator. We recorded whether interventions were 
explicitly reported as usual care or “standard of care”. Trial data collection was classified as 
review of patient medical records, data query from a clinical data registry or other central source 
of routinely collected data, or the use of any direct intervention upon or interaction with 
participants for data collection, including physical examination not required for normal patient 
care, or interactions such as specimen collection, surveys or interviews.  
For each trial, we recorded whether there was an explicit rationale provided for the 
choice of a CRT design, as required by the CONSORT extension for CRTs.6 We also classified 
the type of rationale as one or more of the following: to avoid treatment contamination, logistical 
or administrative convenience, to reduce trial costs, to enhance compliance, to secure 
cooperation of clusters, to achieve herd immunity or study direct and indirect effects of 
interventions in infectious disease settings, and other (with explanation). Within the category of 
“other”, we identified any rationales that referred to the need to facilitate pragmatic trial design. 
When no rationale was provided, abstractors were asked to indicate any apparent rationale, using 
their judgement.  
Informed consent in CRTs can apply with respect to study interventions or data collection 
(or both), thus we abstracted such information separately.24 We classified the type of consent (if 
reported) as written, verbal, deferred, or waived or no consent; we also classified cases where 
consent was unclear or not mentioned. In case of a waiver of consent, we recorded any reported 
justification for the waiver.  
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Analysis 
We conducted a descriptive synthesis of the characteristics and features of included 
studies, summarizing results using frequencies and percentages for categorical variables and 
medians and interquartile intervals for continuous variables. Two-sided 95% confidence intervals 
were calculated for the main outcomes.  
 
RESULTS 
Identification of relevant articles 
The flow diagram depicting the identification and screening of articles is presented in 
Figure 1. Database searching identified 10,045 records; 3,097 possible primary reports of CRTs 
remained after pre-processing and were exported to an Excel spreadsheet and sorted in random 
sequence for full-text searching (Figure 1). A total of 1,198 articles had to be screened to identify 
the required sample. The main reasons for excluding articles at the full-text stage were non-
health care interventions, or interventions included some cluster-level or professional-level 
components.  
Description of included studies 
Characteristics of the included trials are presented in Table 1. Trials were conducted in 27 
different countries; about half were in a LMIC. Units of randomization were diverse, but the 
most commonly used were residential areas, hospitals and intensive care units (ICUs). The 
median of the number of clusters randomized was 24 and median of the average cluster size 
analysed for the primary outcome was 115. The majority used a parallel arm design, but cluster 
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cross-overs and stepped wedge trials25 were also present in our sample. All but one study 
reported review by a research ethics committee. Less than half self-identified as pragmatic. The 
majority of trials used an active control (i.e., comparative effectiveness research), while less than 
a quarter reported a non-protocolized control arm. The 40 trials included in our sample were 
published in 21 different journals (Supplementary Table 3) with impact factors ranging from 
1.12 to 59.56 (median 14.43). 
Study interventions and data collection procedures 
Characteristics of the study interventions and data collection procedures are presented in 
Table 2. The most commonly used intervention type was pharmacological or pharmacological 
treatment strategy. The intervention was explicitly reported by investigators as “usual care” or 
“standard of care” in 7 trials. Close to half of the trials used data extracted from patient medical 
records. Over half used specimen collection (such as blood tests) or physical examination not 
required for normal patient care, and over half involved interaction with patients through 
completion of study questionnaires. Nine trials used solely routinely collected data (e.g., review 
of patient medical charts or downloaded data from a central source).  
Rationale for the use of cluster randomization 
Reported and apparent rationales for adopting cluster randomization are presented in 
Table 3. A total of 25 trials (62.5%, 95% confidence interval (CI) 47.5 to 77.5%) provided an 
explicit rationale for the use of cluster randomization, while 15 (37.5%) provided no rationale. 
The median (25th to 75th percentile) journal impact factor for trials with an explicit rationale was 
14.4 (3.6 to 39.2) and without an explicit rationale 11 (4.2 to 39.1). More than one rationale was 
possible in any trial. The most commonly reported rationales were logistical or administrative 
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convenience and the need to avoid contamination (over half of trials). Five trials reported 
rationales related to the need for a more pragmatic trial or to ensure external validity. Other 
reported reasons were to enhance compliance, to reduce study costs, to achieve herd immunity or 
study direct and indirect effects of interventions in infectious disease settings, to secure 
cooperation of clusters, and to maintain blinding. Among the 15 trials with no explicit rationale 
for cluster randomization provided, reviewers could identify a possible or apparent rationale in 
all 15.  
Informed consent 
Reporting of informed consent in the intervention and control arms was similar and we 
present information only for the intervention arm in Table 4. A total of 21 trials (52.5%, 95% CI 
37 to 68%) reported seeking written informed consent for the study intervention, while 2 (5%) 
reported verbal informed consent; 8 (20%) reported a waiver of consent, while in 9 (22.5%), 
consent for the intervention was either not mentioned or it was unclear. With respect to consent 
for data collection, 20 trials (50%) reported written informed consent for data collection, while 3 
(7.5%) reported verbal consent; 3 (7.5%) reported a waiver of consent, while in 14 (35%), 
consent for data collection was not mentioned or it was unclear. The median (25th to 75th 
percentile) journal impact factor for the 23 trials reporting written or verbal informed consent for 
study interventions was 5.22 (3.53 to 38.28) and for the remaining 17 trials was 30.8 (5.78 to 
47.05). 
Justifications for consent waivers were reported in 6 of 8 trials with waivers of consent 
for study interventions. Only one trial provided a justification consistent with international 
research ethics guidelines, by stating that the study constitutes no more than minimal risk, the 
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research could not be carried out without a waiver, the waiver will not adversely affect the rights 
and welfare of patients, and patients will be provided with pertinent information. Other provided 
reasons were: interventions are usual care interventions involving only minimal risk; the 
interventions constitute standard of care and patients were given pertinent information by means 
of posters placed in waiting rooms; the waiver was justified because of the pragmatic nature of 
the trial; the research was conducted in an emergency situation; consent was unnecessary 
because patients were not randomized individually and interventions are commonly used in 
current practice.  
Association between reporting a rationale for cluster randomization and informed consent  
Table 5 presents the association between reporting of written or verbal consent for study 
interventions and rationales for cluster randomization. When considering the trials with explicit 
rationale provided for cluster randomization, just over half reported either written or verbal 
consent for the study intervention; this proportion was slightly higher among trials without 
explicit rationales. The reporting of written or verbal consent varied according to the type of 
rationale, ranging from a prevalence of 40% among trials with pragmatic rationales, to 75% 
among trials with rationales related to herd immunity.  
 
DISCUSSION 
Our review of a random sample of 40 reports of individual-cluster trials with health care 
interventions found that just over half reported written informed consent for study interventions, 
while one in five explicitly reported a waiver of consent. Justifications for waivers were not 
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always provided and when provided, were consistent with minimum criteria for waivers outlined 
in international research ethics guidance in only one trial. Further, contrary to reporting 
requirements for CRTs,6 more than a third of trials did not report a clear rationale for the use of 
the CRT design. When a rationale for the use of a CRT design was provided, the most common 
rationales were logistical or administrative convenience and the need to avoid contamination. We 
also found justifications for the use of cluster randomization and waivers of consent related to 
the need to facilitate the pragmatic aims of the trial.  
We did not anticipate the need to avoid contamination to be a frequently used rationale as 
our study was focused on clinical interventions such as pharmacological treatments; we excluded 
trials of behavioural, educational or health promotion interventions in which the risk of 
contamination might be higher (for example, due to individuals in the same cluster sharing 
information about the trial). A possible explanation is that many of our trials were conducted in 
LMIC settings in which randomization errors within communities and medication sharing can 
contribute to a form of contamination. Furthermore, nearly half of the trials in our sample 
involved pharmacological treatment strategies (rather than pharmacological treatments per se) in 
which there may be a risk of contamination when the same provider is expected to administer the 
intervention to multiple patients in their care.  
Our study has several limitations. First, our sample size of 40 trials was based on 
logistical considerations and is small (although it is similar to sample sizes in two other reviews 
that considered design justifications for CRTs).26,23 Second, our results are dependent on the 
completeness and clarity of reporting, and we did not contact corresponding authors to obtain 
additional information. However, given that we were interested in documenting the quality of 
reporting, and the presence of trial design and reporting practices that are ethically problematic, 
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asking investigators to explain their design choices after the fact runs the risk of them providing 
a post-hoc justification that would not be a true indicator of the pre-trial rationale. Third, we 
could not classify rationales as appropriate or inappropriate, as it was not possible to dispute a 
provided rationale without detailed knowledge of the trial; thus, we were unable to examine the 
extent to which investigators might be adopting cluster randomization under the mistaken 
perception that it can avoid or lessen the need for informed consent.  
To our knowledge, this is the first study to examine rationales for the choice of cluster 
randomization in the case of exclusively individual-level interventions and the relationship to 
consent practices in the trial. In a review of a random sample of 300 CRTs from 2000-2008, 94 
(31%) reported a rationale for the use of cluster randomization, and 178 (59%) reported 
individual-level consent for any aspect of the trial (data collection, study interventions),22 but 
that review did not consider the subset of trials with exclusively individual-level health care 
interventions. Brierley and colleagues reviewed 24 CRTs published in 2008 in four leading 
medical journals to identify studies in which individual randomization may have been possible 
and to assess the risk of selection bias.26 They found that in 16 (67%), there was a clear rationale 
for cluster randomization and individual randomization would not have been possible. The main 
reasons identified for cluster randomization were to avoid contamination, logistical 
considerations especially in LMIC settings, and the use of cluster-level interventions.  
The adequacy of justifications for adopting cluster randomization with waivers of consent 
has received little attention, yet, such designs are becoming increasingly possible with the 
availability of routinely collected data for outcome assessment. By eliminating the need to 
recruit, randomize and follow individual patients within each center, such designs can 
substantially reduce the costs and logistical complexity of the research, promote external validity 
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by facilitating the inclusion of entire patient populations and centers that may lack research 
infrastructure, and promote internal validity by avoiding a key risk of bias due to post-
randomization recruitment. However, there is a concern that potential misconceptions over the 
use of waivers of consent and logistical advantages to this design that derive from avoiding 
research ethics requirements, might create the potential for the gaming of research oversight 
processes. Generally, CRTs involving human research participants should be considered research 
and submitted for approval by a research ethics committee. Funders, research ethics committees 
and journal editors should require investigators to provide a clear rationale for the choice of 
cluster over individual randomization. Individual randomization should generally be preferred as 
it avoids risks of identification and recruitment biases, as well as the sample size penalty of 
cluster randomization.27 Furthermore, researchers, regulators and research ethics committees 
need to apply the same standard for a waiver of informed consent, regardless of trial design, i.e., 
infeasibility without the waiver, research is of important social value, and poses minimal risks of 
harm.7 The use of cluster randomization, in itself, should not imply a lower standard for 
informed consent.5 It is possible that investigators perceive research ethics committees as being 
more inclined to grant waivers of consent for an intervention when it is evaluated in a cluster 
randomized design than in an individually randomized design, because the larger sample size 
required by a cluster randomized design makes it easier to justify the waiver based on the 
infeasibility criterion — but this is circular reasoning. The decision to adopt cluster rather than 
individual randomization should be independently justified using scientific, practical, and 
logistical considerations — whether a waiver of consent for an individual-level intervention is 
appropriate is a separate issue.  
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While individual-cluster trials are currently a small fraction of all CRTs, we anticipate 
that there will be a rise in the use of this design with the increasing emphasis on pragmatic 
comparative effectiveness research.28 Explicit guidance regarding alternative approaches to 
consent (other than waivers) that are compatible with pragmatic trial aims is needed, for 
example, integrated consent.29 Guidance is also needed on what constitutes “infeasibility” of 
consent, as opposed to mere inconvenience or inefficiency: a recent review of international ethics 
guidance indicated no consensus on when informed can be waived for infeasibility reasons.30 
Finally, explicit guidance is needed to help researchers and research ethics committees judge the 
legitimacy of CRT design justifications, including when individual-level interventions can be 
conceptualized as cluster-level policies (thus, implying the need for cluster randomization). Our 
international, interdisciplinary team has recently been funded to study these issues in more depth 
and to develop guidance for the ethical design and conduct of pragmatic randomized controlled 
trials.31 
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Table 1: Characteristics of trials included in review (N=40) 
Characteristic Frequency (%) 
Publication year 
   2007-2010 
   2011-2013 
   2014-2016 
 
9 (22.5%) 
20 (50.0%) 
11 (27.5%) 
Journal Impact Factor 
Median (Q1-Q3) 
 
14.4 (3.6 – 39.2) 
Country of study conduct 
   Canada 
   USA 
   Canada and USA 
   United Kingdom 
   Elsewhere in the European Union 
   Australia 
   LMICs 
 
1 (2.5%) 
5 (12.5%) 
1 (2.5%) 
4 (10%) 
7 (17.5%) 
1 (2.5%) 
21 (52.5%) 
Types of clusters 
   Residential areas 
   Primary care practices 
   Individual health professionals 
   Hospitals 
   Nursing homes 
   Medical clinics 
   Intensive Care Units 
   Other 
 
15 (37.5%) 
4 (10%) 
2 (5%) 
6 (15%) 
3 (7.5%) 
2 (5%) 
4 (10%) 
4 (10%) 
Funding source 
   Industry alone 
   Government alone 
   Foundation/university alone 
   Multiple sources of funding 
   None reported 
 
1 (2.5%) 
13 (32.5%) 
10 (25.0%) 
15 (37.5%) 
1 (2.5%) 
Number of clusters randomized 
Median (Q1-Q3) 
 
24 (12.5 – 52.5) 
Average cluster size 
   Median (Q1-Q3) 
 
115 (35 – 391) 
Trial design 
   Parallel arm 
   Factorial 
   Cross-over 
   Stepped wedge 
 
28 (70%) 
3 (7.5%) 
6 (15%) 
3 (7.5%) 
Reported presence of a DSMC  16 (40%) 
Self-identified as pragmatic trial 16 (40%) 
Research ethics review reported 39 (97.5%) 
Type of control arm  
   Non-protocolized care (no active intervention) 9 (22.5%) 
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   Placebo or sham treatment 2 (5%) 
   Augmented care 2 (5%) 
   Active control (alternative health care intervention) 24 (60%) 
   Other (e.g., vaccine for an unrelated condition) 3 (7.5%) 
DSMC = Data Safety Monitoring Committee 
LMIC = Low-and-Middle-Income Country  
Q1=First quartile 
Q3=Third quartile 
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Table 2: Characteristics of study interventions and data collection procedures included in 
review (N=40) 
Characteristics Intervention arm 
Frequency (%) 
Control arm 
Frequency (%) 
Types of study interventions*   
   Pharmacological 23 (57.5%) 13 (41.9%) 
   Pharmacological treatment strategy 19 (47.5%) 13 (41.9%) 
   Non-pharmacological treatment strategy 7 (17.5%) 9 (29.0%) 
   Non-implantable device 1 (2.5%) 1 (2.5%) 
Study interventions reported as “usual care” or 
“standard of care”? 
   Yes  
   No 
   Unclear 
 
 
7 (17.5%) 
32 (80%) 
1 (2.5%) 
 
 
34 (85%) 
3 (7.5%) 
3 (7.5%) 
Types of data collection interventions   
   Review of medical records 
   Clinical registry or routine database 
  Specimen collection or physical exam not required for 
normal patient care 
   Interviewer-administered questionnaire 
   Self-administered questionnaire 
   Primary data collection (electronic case record forms)  
19 (47.5%) 
8 (20%) 
23 (57.5%) 
 
17 (42.5%) 
7 (17.5%) 
13 (32.5%) 
19 (47.5%) 
8 (20%) 
22 (55%) 
 
17 (42.5%) 
6 (15%) 
13 (32.5%) 
Solely routinely collected data 9 (22.5%) 9 (22.5%) 
*A trial could be classified as having more than one type of intervention.  
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Table 3: Reported and apparent rationales for the use of cluster randomization (N=40) 
 Frequency (%) 
Trials with explicit rationale provided 25 (62.5%) 
Type of rationale provided* 
   Logistical or administrative convenience 
   To avoid contamination 
   To be more pragmatic or enhance external validity 
   To enhance compliance  
   To reduce costs 
   Herd immunity or to study direct and indirect effects of interventions 
   To secure cooperation of clusters 
   To maintain blinding  
 
15 (60%) 
13 (52%) 
5 (20%) 
5 (20%) 
3 (12%) 
4 (16%) 
2 (8%) 
2 (8%) 
Trials with no explicit rationale provided 15 (37.5%) 
Apparent rationale (in reviewers’ judgement)* 
   Logistical or administrative convenience 
   To avoid contamination 
   Herd immunity or to study direct and indirect effects of interventions 
   To allow physicians to prescribe the same treatment for all their patients  
 
13 (86.7%) 
7 (46.7%) 
8 (53.3%) 
2 (13.3%) 
*A trial could be classified as having more than one type of rationale. 
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Table 4: Reporting of informed consent procedures in the intervention arm (N=40) 
Characteristics Frequency (%) 
Consent for study interventions  
   Written informed consent 
   Verbal informed consent 
   Waiver of consent or no consent 
21 (52.5%) 
2 (5%) 
8 (20%) 
   Consent unclear or not mentioned 9 (22.5% 
Consent for data collection  
   Written informed consent 
   Verbal informed consent 
   Waiver of consent or no consent 
20 (50%) 
3 (7.5%) 
3 (7.5%) 
   Consent unclear or not mentioned 14 (35%) 
Any consent  
   Explicitly reported written or verbal consent for both study 
interventions and data collection  
   Explicitly reported waiver of consent for both study interventions and 
data collection  
   Explicitly reported waiver of consent for study intervention but written 
or verbal consent for data collection 
   Unclear 
 
18 (45%) 
 
3 (7.5%) 
 
3 (7.5%) 
 
16 (40%) 
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Table 5: Association between rationales for the use of cluster randomization and reporting 
of written or verbal informed consent (N=40) 
 Frequency 
(%) 
Written or verbal consent 
for study interventions? 
  Yes No 
Trials with explicit rationale provided 25 (62.5%) 13 (52.0%) 12 (48%) 
Type of rationale provided 
   Logistical or administrative convenience 
   To avoid contamination 
   To be more pragmatic or enhance external validity 
   To enhance compliance  
   To reduce costs 
   Herd immunity or to study direct and indirect 
effects of interventions 
   To secure cooperation of clusters 
   To maintain blinding 
 
15 (60%) 
13 (52%) 
5 (20%) 
5 (20%) 
3 (12%) 
4 (16%) 
 
2 (8%) 
2 (8%) 
 
8 (53.3%) 
7 (53.9%) 
2 (40%) 
3 (60%) 
1 (33.3%) 
3 (75%) 
 
1 (50%) 
1 (50%) 
 
7 (46.7%) 
6 (46.2%) 
3 (60%) 
2 (40%) 
2 (66.7%) 
1 (25%) 
 
1 (50%) 
1 (50%) 
Trials with no explicit rationale provided 15 (37.5%) 10 (66.7%) 5 (33.3%) 
Apparent rationale (in reviewers’ judgement) 
   Logistical or administrative convenience 
   To avoid contamination 
   Herd immunity or to study direct and indirect 
effects of interventions 
   To allow physicians to prescribe the same 
treatment for all their patients  
 
13 (86.7%) 
7 (46.7%) 
8 (53.3%) 
 
2 (13.3%) 
 
9 (69.2%) 
5 (71.4%) 
5 (62.5%) 
 
2 (100%) 
 
4 (30.8%) 
2 (28.6%) 
3 (37.5%) 
 
0 
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FIGURE LEGENDS 
 
Figure 1: Study flow diagram 
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Records after removing duplicates  
(n =10,014) 
1st round - Records 
screened 
(n = 10,014) 
Records excluded as 
obviously ineligible 
(n =5,757) 
2nd round – Records 
screened 
(n = 4,257) 
Records excluded (n = 1,160) 
• Conference abstract (397) 
• Study protocol (300) 
• Not a CRT (144) 
• Secondary analysis (229) 
• Duplicate record (29) 
• Non-English (21) 
• No abstract (4) 
• Other (erratum, letter) (36) 
Studies exported to Excel for 
random sort and full-text 
screen (n = 3,097) 
Studies included in review 
(n = 32) 
Records not screened (1,899) 
Records excluded (n = 1,158) 
• Non- therapeutic intervention 
(768) 
• Cluster-level or professional-
level intervention (337) 
• Not a CRT (11) 
• Secondary analysis (32) 
• Conference abstracts (9) 
• Conducted outside of countries 
of interest (1) 
Non-randomly selected 
pilot studies (n = 8) 
Total studies included in 
review (n = 40) 
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Supplementary Table 1: Common reasons for adopting cluster randomization and 
applicability to individual-cluster trials with therapeutic interventions 
Reason Explanation Usually applies to 
individual health-
care interventions? 
Intervention is 
inherently a cluster-
level intervention  
Due to the nature of the intervention, exposure is 
involuntary, and cluster randomization is the 
only feasible choice  
No  
Intervention is 
administered to 
health professionals 
in each cluster 
In case of educational or behaviour change 
interventions, it would not be appropriate or 
feasible to ask professionals to treat both 
experimental and control patients  
No  
To avoid a high risk 
of treatment 
contamination 
In case of behavioural, educational, or health 
promotion interventions, individuals in the same 
cluster but randomized to different arms may 
share information about the trial and bias the 
intervention effect towards the null; in LMIC 
settings, community members may share 
medications to increase the chances of receiving 
an active treatment 
May apply, especially 
in LMIC settings  
To simplify trial 
logistics 
It can simplify the trial organization if there is 
only one type of treatment in each cluster; in 
LMIC settings, it can minimize the risk of errors 
if fieldworkers only need one type of treatment 
in their possession and don’t have to keep track 
of individual allocations  
Yes, especially in 
LMIC settings 
To reduce costs When the intervention involves provision of staff 
or expensive equipment, a CRT can reduce costs 
in that only half of participating sites need to be 
supplied rather than all sites  
Not usually; a CRT 
increases the sample 
size and therefore, 
costs of recruitment 
Herd immunity or to 
study direct and 
indirect effect of 
intervention 
In trials of treatments for infectious diseases, 
individual randomization might be impractical 
because some individuals allocated to the control 
arm may nevertheless receive protection through 
herd immunity; moreover, both direct and 
indirect effects of intervention may be of interest  
Applies to some types 
of treatments 
To enhance 
compliance  
For some interventions (e.g., behavioural or 
health promotion), compliance may be enhanced 
through interactions amongst cluster members  
Not generally 
To facilitate 
recruitment 
Gatekeepers or communities may not be willing 
to participate unless all their members receive 
intervention; to avoid resentment amongst 
community members who don’t receive an 
intervention perceived to be beneficial 
May apply to some 
types of treatments, 
especially in LMIC 
settings  
LMIC = Low-and-Middle-Income Country   
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Supplementary Table 2: Electronic search filter to identify cluster randomized trials  
 
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1. controlled trial.pt. (469686) 
2. Analysis/ (58846) 
3. (cluster* adj2 random*).tw. (11394) 
4. ((communit* adj2 intervention*) or (communit* adj2 randomi*)).tw. (6985) 
5. group* randomi*.tw. (2887) 
6. or/2-5 (77174) 
7. 1 and 6 (8878) 
8. cluster rct*.tw. (422) 
9. (cluster adj2 random* controlled trial*).tw. (3745) 
10. 7 or 8 or 9 (10275) 
11. limit 10 to yr="2007 -Current" (8642) 
12. animals/ not humans/ (4635939) 
13. 11 not 12 (8624) 
 
 
Database: Embase Classic+Embase <1947 to 2016 November 16>  
Search Strategy: 
-------------------------------------------------------------------------------- 
1. double-blind*.mp. or placebo*.tw. or blind*.tw. (497090) 
2. *randomized controlled trial/ (37865) 
3. 1 or 2 (523172) 
4. cluster analysis/ (48160) 
5.  (cluster* adj2 random*).tw. (11592) 
6.  ((communit* adj2 intervention*) or (communit* adj2 randomi*)).tw. (7433) 
7. group* randomi*.tw. (2881) 
8. or/4-7 (67327) 
9. 3 and 8 (4327) 
10. cluster rct*.tw. (392) 
11.  (cluster adj5 trial*).tw. (7382) 
12. or/9-11 (9977) 
13.  (exp animal/ or nonhuman/) not exp human/ (6147352) 
14. 12 not 13 (9912) 
15. limit 14 to yr="2007 -Current" (8530) 
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Supplementary Table 3: Journals where N=40 CRTs included in the review were published 
 Acta Paediatrica (1) 
 Am J Trop Med Hyg (1) 
 BMC Pregnancy and Childbirth (1)  
 Br J Psychiatry (1)  
 Circulation (1) 
 Clinical Infectious Diseases (1) 
East African Medical Journal (1) 
 Headache (1)  
 Infection Control and Hospital Epidemiology (1)  
 JAMA (2)  
Journal of Clinical Nursing (1) 
 Lancet (8) 
 Malaria (1) 
 NEJM (7) 
 PLOS Medicine (3) 
 PLOS Neglected Tropical Diseases (2) 
 PLOS ONE (2) 
 Pediatrics (1) 
 Sexually transmitted diseases (1) 
 The Journal of Infectious Diseases (1) 
 Vaccine (2) 
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